New drug combo shows promise for tough lung cancer
NCT ID NCT03083041
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, SHR-1210 (given through a vein) and Apatinib (a daily pill), in 210 adults with advanced non-small cell lung cancer that had stopped responding to standard chemotherapy. The goal was to see if the combo could shrink tumors and to check for side effects. Participants received one of two doses of Apatinib along with SHR-1210, and their tumors were monitored over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Can an oral chemo pill boost immunotherapy's power against lung cancer?
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Immunotherapy boosts radiation against early lung cancer
- Lab-Grown lung tumors could reveal why some drugs work and others fail
- AI-Powered navigation aims to pinpoint tiny lung nodules during surgery